A Tumor-Localized Approach to Bypass Anti-4-1BB Immuno-Toxicity

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Tina Tianjiao SuJun Wang

Abstract

4-1BB (CD137) is an important costimulatory molecule upregulated on antigen-experienced T cells, however, clinical development of 4-1BB agonists has stalled because of significant liver immuno-toxicity. Using rational protein engineering, a next-generation anticalin-antibody-based therapy achieved localized 4-1BB activation triggered by tumor-expressed antigen, helping to revitalize this pathway in immuno-oncology.See related article by Hinner et al., p. 5878.

References

Nov 10, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jun WangShengdian Wang
May 30, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Marlon J HinnerShane Anthony Olwill

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
Jun-ying WuBai-qing Li
The American Journal of Managed Care
Bruce A FeinbergChadi Nabhan
© 2021 Meta ULC. All rights reserved